Servicio de Neumología, Complexo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain.
Int J Tuberc Lung Dis. 2011 Oct;15(10):1403-8. doi: 10.5588/ijtld.10.0648.
To analyse slow-acetylation N-acetyltransferase 2 (NAT2) polymorphisms for their association with the risk of anti-tuberculosis drug-induced hepatotoxicity (ATDH).
A case-control study including Caucasian patients with tuberculosis (TB) treated with isoniazid, rifampicin and pyrazinamide. NAT2 genotype results were compared between ATDH cases and controls and with a healthy Spanish control population of Caucasian origin.
Fifty cases and 67 controls were included in the study. Slow, intermediate and rapid NAT2 genotypes were found in respectively 72%, 18% and 10% of cases compared with 65.7%, 25.4% and 9% of controls (P> 0.05). On comparing NAT2 genotypes among cases with those among healthy controls (n = 1312), we found more slow NAT2 genotypes and fewer intermediate genotypes among cases (respectively 72% and 18% in cases vs. 54.8% and 38.1% in controls; OR 2.07, 95%CI 1.12-2.79, P = 0.016 and OR 0.37, 95%CI 0.18-0.75, P = 0.003).
We could not demonstrate an increased risk of ATDH related to the presence of slow NAT2 polymorphisms among this Caucasian TB cohort. However, we found a significantly greater frequency of slow and a significantly lower frequency of intermediate NAT2 genotypes among the ATDH cases compared with the healthy control population.
分析慢乙酰化 N-乙酰基转移酶 2（NAT2）多态性与抗结核药物性肝损伤（ATDH）风险的关系。
一项包括接受异烟肼、利福平和吡嗪酰胺治疗的白种人肺结核（TB）患者的病例对照研究。比较 ATDH 病例与对照以及与西班牙白种人健康对照人群的 NAT2 基因型结果。
本研究纳入了 50 例病例和 67 例对照。病例组中慢、中、快 NAT2 基因型分别为 72%、18%和 10%，对照组分别为 65.7%、25.4%和 9%（P>0.05）。比较病例组和健康对照组（n=1312）的 NAT2 基因型，我们发现病例组中慢 NAT2 基因型更多，中间基因型更少（病例组分别为 72%和 18%，对照组分别为 54.8%和 38.1%；OR 2.07，95%CI 1.12-2.79，P=0.016 和 OR 0.37，95%CI 0.18-0.75，P=0.003）。
我们未能证明在这个白种人 TB 队列中，慢 NAT2 多态性与 ATDH 风险增加相关。然而，我们发现 ATDH 病例组中慢和中间 NAT2 基因型的频率显著更高，而健康对照组的频率显著更低。
